These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 19273808)
1. Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus. Silkiss RZ; Lee H; Gills Ray VL Arch Ophthalmol; 2009 Mar; 127(3):345-6. PubMed ID: 19273808 [No Abstract] [Full Text] [Related]
2. EU issues warning about HAART regimen. AIDS Patient Care STDS; 2004 Jan; 18(1):56-7. PubMed ID: 15080094 [No Abstract] [Full Text] [Related]
3. Blepharoptosis and HAART related mitochondrial myopathy. Chapman KO; Lelli G Orbit; 2014 Dec; 33(6):459-61. PubMed ID: 25215893 [TBL] [Abstract][Full Text] [Related]
4. The continuing evolution of HIV therapy. Boyle BA AIDS Read; 2003 Dec; 13(12):576-8, 582. PubMed ID: 14959692 [No Abstract] [Full Text] [Related]
5. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. Leeansyah E; Cameron PU; Solomon A; Tennakoon S; Velayudham P; Gouillou M; Spelman T; Hearps A; Fairley C; Smit de V; Pierce AB; Armishaw J; Crowe SM; Cooper DA; Koelsch KK; Liu JP; Chuah J; Lewin SR J Infect Dis; 2013 Apr; 207(7):1157-65. PubMed ID: 23303810 [TBL] [Abstract][Full Text] [Related]
6. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml. Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354 [TBL] [Abstract][Full Text] [Related]
7. Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen. Lacombe K; Pacanowski J; Meynard JL; Trylesinski A; Girard PM AIDS; 2005 Jul; 19(10):1107-8. PubMed ID: 15958845 [TBL] [Abstract][Full Text] [Related]
8. Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman. Ripamonti D; Maggiolo F; Suter F AIDS; 2007 May; 21(8):1059-60. PubMed ID: 17457107 [No Abstract] [Full Text] [Related]
9. What's new, what's next? Elwell A Posit Dir News; 1999; 11(1):1, 3-13. PubMed ID: 11366098 [TBL] [Abstract][Full Text] [Related]
10. Warning issued on non-response rates. AIDS Patient Care STDS; 2003 Oct; 17(10):539. PubMed ID: 14588094 [No Abstract] [Full Text] [Related]
11. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Lang S; Mary-Krause M; Cotte L; Gilquin J; Partisani M; Simon A; Boccara F; Costagliola D; Arch Intern Med; 2010 Jul; 170(14):1228-38. PubMed ID: 20660842 [TBL] [Abstract][Full Text] [Related]
12. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. Gianotti N; Galli L; Bocchiola B; Cahua T; Panzini P; Zandonà D; Salpietro S; Maillard M; Danise A; Pazzi A; Lazzarin A; Castagna A HIV Med; 2013 Mar; 14(3):153-60. PubMed ID: 22994659 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study). Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469 [No Abstract] [Full Text] [Related]
14. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS; AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866 [TBL] [Abstract][Full Text] [Related]
15. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Elzi L; Marzolini C; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M; Arch Intern Med; 2010 Jan; 170(1):57-65. PubMed ID: 20065200 [TBL] [Abstract][Full Text] [Related]
16. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV]. Bayonne Kombo ES; Gathse A Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355 [No Abstract] [Full Text] [Related]
17. Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. Maggiolo F; Roat E; Pinti M; Nasi M; Gibellini L; De Biasi S; Airoldi M; Ravasio V; Mussini C; Suter F; Cossarizza A Antivir Ther; 2010; 15(1):51-9. PubMed ID: 20167991 [TBL] [Abstract][Full Text] [Related]
18. Severe recurrent rhabdomyolysis-induced acute kidney injury in a HIV-infected patient on antiretroviral therapy. Spiegel LR; Schrier PB; Shah HH Ren Fail; 2013 Sep; 35(8):1186-90. PubMed ID: 23883141 [TBL] [Abstract][Full Text] [Related]
19. Novel approaches for the treatment of HIV. Arroyo HT Newsline People AIDS Coalit N Y; 1998 Mar; ():16-7. PubMed ID: 11367450 [TBL] [Abstract][Full Text] [Related]
20. [Current data on antiretroviral therapy. CROI 2009: tenofovir DR convinces by high effectiveness and tolerance]. Walter M MMW Fortschr Med; 2009 Apr; 151(18):76-9. PubMed ID: 19769084 [No Abstract] [Full Text] [Related] [Next] [New Search]